CAR-T cell therapy for cancer: current challenges and future directions
Por:
Zugasti, I, Espinosa-Aroca, L, Fidyt, K, Mulens-Arias, V, Diaz-Beya, M, Juan, ME, Urbano-Ispizua, A, Esteve, J, Velasco-Hernandez, T and Menendez, P
Publicada:
4 jul 2025
Ahead of Print:
4 jul 2025
Resumen:
Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effective and safe, as AML cells share most surface antigens with healthy hematopoietic stem and progenitor cells (HSPCs). Simultaneously targeting antigen expression on both AML cells and HSPCs may result in life-threatening on-target/off-tumor toxicities such as prolonged myeloablation. In addition, the immunosuppressive nature of the AML tumor microenvironment has a detrimental effect on the immune response. This review begins with a comprehensive overview of CAR-T cell therapy for cancer, covering the structure of CAR-T cells and the history of their clinical application. It then explores the current landscape of CAR-T cell therapy in both hematologic malignancies and solid tumors. Finally, the review delves into the specific challenges of applying CAR-T cell therapy to AML, highlights ongoing global clinical trials, and outlines potential future directions for developing effective CAR-T cell-based treatments for relapsed/refractory AML.
Filiaciones:
Zugasti, I:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Diaz-Beya, M:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Juan, ME:
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Dept Immunol, Barcelona, Spain
Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Hosp Clin Barcelona, Immunotherapy Joint Platform Hosp Sant Joan Deu, Barcelona, Spain
Urbano-Ispizua, A:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Esteve, J:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Velasco-Hernandez, T:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Institucio Catalana Recerca & Estudis Avancats ICR, Barcelona, Spain
Inst Recerca Sant Joan Deu SJD, Pediat Canc Ctr Barcelona PCCB, Barcelona, Spain
Green Submitted, gold
|